Surprise As Amgen Passes Regeneron/Sanofi To First PCSK9 Inhibitor Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
While all eyes were on the U.S. market, Amgen clinched victory over Regeneron/Sanofi in the race to be first to approval with a PCSK9 inhibitor in another major territory, the EU.
You may also be interested in...
How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.
New Phase II Data Bolster vTv Therapeutics’ Glucokinase Activator Aspirations
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed Goes Full Steam Ahead With Bronchiectasis Candidate
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: